Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UBX0101 in painful knee osteoarthritis
NCT04129944Phase 2Completed
- Sponsor
- Unity Biotechnology
- Start
- Oct 2019
- Primary completion
- May 2020
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of UBX0101 in osteoarthritis (OA) (4 arms), sponsored by Unity Biotechnology. Primary endpoint: Western Ontario and McMaster Universities Osteoarthritis Index Pain Subscale at 12 weeks. Started Oct 2019; status: completed.
02
Drugs
UBX0101
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT04129944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04129944.